Propella
Pittsboro
About Propella
Propella Therapeutics is a pharmaceutical company developing innovative lymphatic-targeted oncology therapies. Propella employs medicinal chemistry and lymphatic targeting platform to create oncology drugs starting from known actives that have validated mechanisms of action and biological targets. Lymphatic targeting enables therapies to be delivered directly to targeted tissues via the lymphatic system thereby bypassing first-pass liver effects. The company’s lead drug candidate, PRL-02, is a potential best-in-class CYP17 lyase inhibitor and as such is an androgen receptor (AR) pathway-directed therapy for the treatment of advanced prostate cancer.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Website: propellatx.com
- Phone: +1.855.244.4546
Industries & Categories
Biotechnology, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/propella-828068 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.